- Home
- ALLO vs LEGT Comparison
ALLO vs LEGT Comparison
Compare ALLO & LEGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- LEGT
- Stock Information
- Founded
- ALLO 2017
- LEGT 2023
- Country
- ALLO United States
- LEGT United States
- Employees
- ALLO N/A
- LEGT N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- LEGT
- Sector
- ALLO Health Care
- LEGT
- Exchange
- ALLO Nasdaq
- LEGT Nasdaq
- Market Cap
- ALLO 252.9M
- LEGT 277.1M
- IPO Year
- ALLO 2018
- LEGT 2024
- Fundamental
- Price
- ALLO $1.43
- LEGT $10.74
- Analyst Decision
- ALLO Buy
- LEGT
- Analyst Count
- ALLO 12
- LEGT 0
- Target Price
- ALLO $8.80
- LEGT N/A
- AVG Volume (30 Days)
- ALLO 2.9M
- LEGT 17.9K
- Earning Date
- ALLO 11-06-2025
- LEGT 01-01-0001
- Dividend Yield
- ALLO N/A
- LEGT N/A
- EPS Growth
- ALLO N/A
- LEGT N/A
- EPS
- ALLO N/A
- LEGT 0.35
- Revenue
- ALLO N/A
- LEGT N/A
- Revenue This Year
- ALLO N/A
- LEGT N/A
- Revenue Next Year
- ALLO $100.00
- LEGT N/A
- P/E Ratio
- ALLO N/A
- LEGT $30.60
- Revenue Growth
- ALLO N/A
- LEGT N/A
- 52 Week Low
- ALLO $0.86
- LEGT $10.18
- 52 Week High
- ALLO $3.78
- LEGT $10.86
- Technical
- Relative Strength Index (RSI)
- ALLO 64.79
- LEGT 50.70
- Support Level
- ALLO $1.29
- LEGT $10.72
- Resistance Level
- ALLO $1.43
- LEGT $10.74
- Average True Range (ATR)
- ALLO 0.07
- LEGT 0.01
- MACD
- ALLO 0.02
- LEGT -0.00
- Stochastic Oscillator
- ALLO 78.17
- LEGT 33.33
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
About LEGT Legato Merger Corp. III
Legato Merger Corp III is a blank check company.